- Loading stock data...
HippoFi™ delivers its cutting-edge healthcare innovations and propriety technologies through the Company’s strategic sales channels and extensive distribution networks and is focused on implementing first-to-market solutions in the multibillion-dollar Biotech, Fintech, and AI markets.
HippoFi Regenerative Therapeutics division is actively deploying scalable biological solutions into the $1.37 Trillion (13.96% CAGR) Biotechnology market through its wholly owned subsidiary PUR Biologics.
HippoFi’s biotech company, PUR Biologics is led by a team of industry executives and strategic alliances who have remained at the forefront of the biotech revolution for more than 20 years.
Combining our strategic channel partners and national distribution network with PUR’s innovations and proprietary technologies, PUR’s current and emerging product portfolio is empowering thousands of spine surgeons across the country, placing advanced technologies into their hands to help continually improve surgical outcomes and patient’s quality of life.
( Coded stock chart )
Investor Inquiries
Jason Brown
HippoFi Shareholder Communications
612.209.7565
JBrown@HippoFi.com
Shaping the future with healthcare technologies
Stay connected and be informed about how HippoFi is transforming the business of surgery and its PUR Biologics company continues as the authority in spinal biologics.